ITGAX and neoplasm: Compared to the control group, the cell number of the CD40+ DCs (CD45+CD3e−MHCII+CD40+CD11c+) in the tumor draining lymph nodes was significantly reduced in all treatment groups except α-PD-1 + α-CTLA-4 group (Fig. 4D).